311 related articles for article (PubMed ID: 37569483)
1. Long Non-Coding RNAs in Venous Thromboembolism: Where Do We Stand?
Marques IS; Tavares V; Neto BV; Mota INR; Pereira D; Medeiros R
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569483
[TBL] [Abstract][Full Text] [Related]
2. Long Non-Coding RNAs: Bridging Cancer-Associated Thrombosis and Clinical Outcome of Ovarian Cancer Patients.
Marques IS; Tavares V; Savva-Bordalo J; Rei M; Liz-Pimenta J; de Melo IG; Assis J; Pereira D; Medeiros R
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203310
[TBL] [Abstract][Full Text] [Related]
3. Cancer-associated thrombosis: What about microRNAs targeting the tissue factor coagulation pathway?
Tavares V; Neto BV; Marques IS; Assis J; Pereira D; Medeiros R
Biochim Biophys Acta Rev Cancer; 2024 Jan; 1879(1):189053. PubMed ID: 38092078
[TBL] [Abstract][Full Text] [Related]
4. Role of microRNAs in Venous Thromboembolism.
Morelli VM; Brækkan SK; Hansen JB
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283653
[TBL] [Abstract][Full Text] [Related]
5. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
6. Treatment of DVT: how long is enough and how do you predict recurrence.
Agnelli G; Becattini C
J Thromb Thrombolysis; 2008 Feb; 25(1):37-44. PubMed ID: 17906973
[TBL] [Abstract][Full Text] [Related]
7. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis.
Khan F; Rahman A; Carrier M; Kearon C; Weitz JI; Schulman S; Couturaud F; Eichinger S; Kyrle PA; Becattini C; Agnelli G; Brighton TA; Lensing AWA; Prins MH; Sabri E; Hutton B; Pinede L; Cushman M; Palareti G; Wells GA; Prandoni P; Büller HR; Rodger MA;
BMJ; 2019 Jul; 366():l4363. PubMed ID: 31340984
[TBL] [Abstract][Full Text] [Related]
8. The role of inflammation in venous thromboembolism and the link between arterial and venous thrombosis.
Poredos P; Jezovnik MK
Int Angiol; 2007 Dec; 26(4):306-11. PubMed ID: 18091697
[TBL] [Abstract][Full Text] [Related]
9. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
Huisman MV; Bounameaux H
Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
[TBL] [Abstract][Full Text] [Related]
10. Tissue Factor Pathway Inhibitor 2: A Novel Biomarker for Predicting Asymptomatic Venous Thromboembolism in Patients with Epithelial Ovarian Cancer.
Yamanaka S; Miyake R; Yamada Y; Kawaguchi R; Ootake N; Myoba S; Kobayashi H
Gynecol Obstet Invest; 2022; 87(2):133-140. PubMed ID: 35613543
[TBL] [Abstract][Full Text] [Related]
11. The role of ximelagatran in the treatment of venous thromboembolism.
Schulman S
Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():18-24. PubMed ID: 15812200
[TBL] [Abstract][Full Text] [Related]
12. Tissue factor pathway inhibitor 2 as a serum marker for diagnosing asymptomatic venous thromboembolism in patients with epithelial ovarian cancer and positive D-dimer results.
Miyake R; Yamada Y; Yamanaka S; Kawaguchi R; Ootake N; Myoba S; Kobayashi H
Mol Clin Oncol; 2022 Feb; 16(2):46. PubMed ID: 35003744
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease.
Goto S; Haas S; Ageno W; Goldhaber SZ; Turpie AGG; Weitz JI; Angchaisuksiri P; Nielsen JD; Kayani G; Farjat A; Schellong S; Bounameaux H; Mantovani LG; Prandoni P; Kakkar AK;
JAMA Netw Open; 2020 Oct; 3(10):e2022886. PubMed ID: 33112399
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA MALAT1 suppresses the proliferation and migration of endothelial progenitor cells in deep vein thrombosis by regulating the Wnt/β-catenin pathway.
Du B; Wang J; Zang S; Mao X; Du Y
Exp Ther Med; 2020 Oct; 20(4):3138-3146. PubMed ID: 32855682
[TBL] [Abstract][Full Text] [Related]
15. Home versus in-patient treatment for deep vein thrombosis.
Othieno R; Okpo E; Forster R
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD003076. PubMed ID: 29315455
[TBL] [Abstract][Full Text] [Related]
16. Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design.
Weitz JI; Haas S; Ageno W; Angchaisuksiri P; Bounameaux H; Nielsen JD; Goldhaber SZ; Goto S; Kayani G; Mantovani L; Prandoni P; Schellong S; Turpie AG; Kakkar AK
Thromb Haemost; 2016 Nov; 116(6):1172-1179. PubMed ID: 27656711
[TBL] [Abstract][Full Text] [Related]
17. Neuromuscular electrical stimulation for the prevention of venous thromboembolism.
Hajibandeh S; Hajibandeh S; Antoniou GA; Scurr JR; Torella F
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011764. PubMed ID: 29161465
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
19. Decision support systems in clinical practice: The case of venous thromboembolism prevention.
Nazarenko GI; Kleymenova EB; Payushik SA; Otdelenov VA; Sychev DA; Yashina LP
Int J Risk Saf Med; 2015; 27 Suppl 1():S104-5. PubMed ID: 26639683
[TBL] [Abstract][Full Text] [Related]
20. Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients.
Ay C; Pabinger I
Thromb Res; 2012 Apr; 129 Suppl 1():S6-9. PubMed ID: 22682135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
